The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy

T. Okegawa, Y. Li, R. C. Pong, J. M. Bergelson, J. Zhou, J. T. Hsieh

Research output: Contribution to journalArticle

189 Scopus citations

Abstract

In a recent paper, we reported a significant difference in coxsackie and adenovirus receptor (CAR) from several human bladder cancer cell lines that correlated with their sensitivities to adenoviral infection (Y. Li, R-C. Pong, J. M. Bergelson, M, C. Hall, A. I. Sagalowsky, C-P. Tseng, Z. Wang, and J. T. Hsieh, Cancer Res., 59: 325-330, 1999). In human prostate cancer, CAR protein is down-regulated in the highly tumorigenic PC3 cell line, which suggests that, in addition to its function as a viral receptor, CAR may have a pathophysiological role in prostate cancer progression. In this paper, we document that CAR does not merely enhance the viral sensitivity of prostate cancer cells but also acts as a tumor inhibitor for androgen-independent prostate cancer cells. Our data indicate that CAR is a potential therapeutic agent for increasing the efficacy of prostate cancer therapy.

Original languageEnglish (US)
Pages (from-to)5031-5036
Number of pages6
JournalCancer Research
Volume60
Issue number18
StatePublished - Sep 15 2000

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Okegawa, T., Li, Y., Pong, R. C., Bergelson, J. M., Zhou, J., & Hsieh, J. T. (2000). The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Research, 60(18), 5031-5036.